Article

NDA accepted for kidney cancer agent

AVEO Oncology and Astellas Pharma Inc. have announced that the FDA has accepted for filing the new drug application (NDA) for tivozanib with the proposed indication for the treatment of patients with advanced renal cell carcinoma.

Related Videos
Olivia Paulsen answers a question during a video interview
Evan Panken, MD, answers a question during a video interview
Oliver Sartor, MD, is featured in this series.
Petar Bajic, MD, answers a question during a video interview
Ellen Cahill, MD, answers a question during a video interview
1 KOL is featured in this series.
Related Content
Category I CPT code granted to irreversible electroporation for prostate lesions
October 22nd 2024

Category I CPT code granted to irreversible electroporation for prostate lesions

Hannah Clarke
The codes will go into effect on January 1, 2026.
Key updates from the AUA/ASRM male infertility guideline amendment
September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff
In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.
Sacituzumab govitecan withdrawn from bladder cancer market following negative trial
October 21st 2024

Sacituzumab govitecan withdrawn from bladder cancer market following negative trial

Hannah Clarke
The decision to withdraw sacituzumab govitecan from the market was made in consultation with the US FDA following negative data from the phase 3 TROPiCS-04 trial.
Speaking of Urology: Dr. Winter on the use of vaginal estrogen
July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff
In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.
Low-intensity shockwave therapy, plasma injections efficacious for erectile dysfunction
October 20th 2024

Low-intensity shockwave therapy, plasma injections efficacious for erectile dysfunction

Kevin Kunzmann
SMSNA 2024 abstract data show shockwave therapies and platelet-rich plasma, either alone or in combination, may be promising treatments for ED.
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
October 20th 2024

CCH appears safe, efficacious in Peyronie disease with ventral curvature

Benjamin P. Saylor
68.8% of patients had at least a 30% improvement in ventral curvature from baseline.
© 2024 MJH Life Sciences

All rights reserved.